At this year’s Annual General Assembly of Athebio AG, a biotech company enabling drug developers to create superior targeted therapeutics of advanced efficacy and safety by harnessing its proprietary “plug & play” Athebody DARPin technology platform, the shareholders of the company elected Dr. Hans-Peter Gerber, PhD, as new member of the Board of Directors.
After serving Athebio’s Advisory Board since March of this year, he will continue to support the company’s research and partnering strategies.
Dr. Gerber is an industry veteran and internationally recognized leader with over 25 years of R&D experience in oncology drug development, including antibody-drug conjugates (ADCs), T-cell engagers (TCEs, “bispecifics”) and adoptive T-cell therapies (TCR-T and CAR-T cells). Starting at Genentech (11 years), Seattle Genetics (3 years) and Pfizer (8 years), he continued serving various executive roles in different companies (e.g., Maverick Therapeutics, 3T Biosciences, Codeable Therapeutics).
During his career, Dr. Gerber built highly successful drug development teams in pharma, biotech and startup companies and oversaw preclinical development programs for targeted therapeutics in oncology (including target ID, platform- and preclinical program development). He served on boards and raised money for seed and series A financing for multiple biotech startups. Beyond this background, he served as consultant to various VCs evaluating diverse therapeutic modalities. Currently, he serves as CSO of Codeable Therapeutics, an ADC startup company focusing on the development of next generation ADCs that induce immunogenic cell death.
Patrik Forrer, CEO, commented: “We are delighted and honored to welcome Hans-Peter to Athebio’s Board! With his broad and deep scientific and entrepreneurial background and his extensive experience in the development of targeted therapeutics, he will continue to bring valuable scientific and drug development know-how to Athebio. As we progress towards establishing Athebody DARPins as “plug & play” building blocks for innovative drugs and move forward with our partnerships, Hans-Peter will play an instrumental role in shaping the future for Athebio and our partners.”
Dr. Gerber added: “Since joining Athebio in March, I have been consistently impressed by the exceptional team and cutting-edge technology. Both are excellently positioned to spearhead the advancement of the next generation of Biotherapeutics. Athebio's proprietary Athebody DARPin platform holds tremendous potential to empower drug developers in creating industry-leading therapeutics. I am eagerly anticipating the opportunity to contribute to shaping Athebio's strategy for introducing this promising technology to innovation leaders worldwide.